Search
Aztreonam
go.drugbank.com/drugs/DB00355ApprovedInvestigationalIt is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
Durlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigational[L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.
Antihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalPEGylation is the covalent attachment of a polyethylene glycol polymer, called PEG, to a drug or protein. … It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label].
Procaine
go.drugbank.com/drugs/DB00721ApprovedInvestigationalVet approvedA local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients [L1215].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, NMDA Receptor AntagonistsNerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigationalNerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. … [L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591]
Anti-inhibitor coagulant complex
go.drugbank.com/drugs/DB13151ApprovedInvestigationalIt is used to control bleeding in hemophilia A and B patients with inhibitors. … Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.
Products: Feiba 25 E./ml Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Feiba 50 E./ml Pulver und Lösungsmittel zur Herstellung einer InfusionslösungSitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalThe effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. … Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256
Mixtures: SITAGLIPTIN E METFORMINA GALENICUM, SITAGLIPTIN E METFORMINA GALENICUMLurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigationalthe substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. … [A214310] It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being
Translocator protein
go.drugbank.com/bio_entities/BE0000736TargetHumansWas initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides (PubMed:1847678)
Synonyms: Mitochondrial benzodiazepine receptor, Peripheral-type benzodiazepine receptorOnasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigationalOnasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. … [L9194] Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA